Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation

Por Hennessy, Edward J., Chuaqui, Claudio, Ashton, Susan, Colclough, Nicola, Cross, Darren A. E., Debreczeni, Judit É., Eberlein, Cath, Gingipalli, Lakshmaiah, Klinowska, Teresa C. M., Orme, Jonathan P., Sha, Li, Wu, Xiaoyun
Publicado no ACS Med Chem Lett (2016)

Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions

Por Floc’h, Nicolas, Martin, Matthew J., Riess, Jonathan W., Orme, Jonathan P., Staniszewska, Anna D., Menard, Ludovic, Cuomo, Maria Emanuela, O'Neill, Daniel J, Ward, Richard A., Finlay, M. Raymond V., McKerrecher, Darren, Cheng, Mingshan, Vang, Daniel P, Tsai, Rebekah A., Keck, James G., Gandara, David R., Mack, Philip C., Cross, Darren, AE
Publicado no Mol Cancer Ther (2018)

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Por Durant, Stephen T., Zheng, Li, Wang, Yingchun, Chen, Kan, Zhang, Lingli, Zhang, Tianwei, Yang, Zhenfan, Riches, Lucy, Trinidad, Antonio G., Fok, Jacqueline H. L., Hunt, Tom, Pike, Kurt G., Wilson, Joanne, Smith, Aaron, Colclough, Nicola, Reddy, Venkatesh Pilla, Sykes, Andrew, Janefeldt, Annika, Johnström, Peter, Varnäs, Katarina, Takano, Akihiro, Ling, Stephanie, Orme, Jonathan, Stott, Jonathan, Roberts, Caroline, Barrett, Ian, Jones, Gemma, Roudier, Martine, Pierce, Andrew, Allen, Jasmine, Kahn, Jenna, Sule, Amrita, Karlin, Jeremy, Cronin, Anna, Chapman, Melissa, Valerie, Kristoffer, Illingworth, Ruth, Pass, Martin
Publicado no Sci Adv (2018)